308430
CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clin… Read more
Market Cap & Net Worth: 308430 (308430)
308430 (KQ:308430) has a market capitalization of $241.63 Million (₩353.80 Billion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #16346 globally and #507 in its home market, demonstrating a 2.99% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 308430's stock price ₩27600.00 by its total outstanding shares 12818825 (12.82 Million).
308430 Market Cap History: 2024 to 2026
308430's market capitalization history from 2024 to 2026. Data shows growth from $103.31 Million to $241.63 Million (0.00% CAGR).
308430 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 308430's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
308430's market cap is 0.05 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $103.31 Million | $2.29 Billion | -$7.27 Billion | 0.05x | N/A |
Competitor Companies of 308430 by Market Capitalization
Companies near 308430 in the global market cap rankings as of March 18, 2026.
Key companies related to 308430 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
308430 Historical Marketcap From 2024 to 2026
Between 2024 and today, 308430's market cap moved from $103.31 Million to $ 241.63 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩241.63 Million | +16.95% |
| 2025 | ₩206.61 Million | +100.00% |
| 2024 | ₩103.31 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of 308430 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $241.63 Million USD |
| MoneyControl | $241.63 Million USD |
| MarketWatch | $241.63 Million USD |
| marketcap.company | $241.63 Million USD |
| Reuters | $241.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.